Close
Smartlab Europe
Achema middle east

Press Releases

Pfizer Inc, Study Shows Adding INSPRA to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure

Pfizer Inc. announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those...

Forest Laboratories Enters Collaboration on Bystolic(R) and Savella(R)

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic(R) (nebivolol) and Savella(R) (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively,...

Endo Pharmaceuticals Announces That FDA Eliminates Need for Advisory Committee Meeting to Discuss New Formulation of Long-Acting Oxymorphone

  Endo Pharmaceuticals announced that the U.S. FDA has informed the company that FDA no longer sees a need to convene a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk...

Abbott Wins Two Scrip Awards Recognizing Excellence in Pharmaceutical and Biotech Industries

Abbott Park, Illinois Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management. Miles D. White, chairman and chief executive officer, Abbott said,...

Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma

Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in...

PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia

PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia (nmMMA). MMA is a rare genetic disorder caused...

Celator Pharmaceuticals completes enrollment in a second phase 2 trail of CPX-351in acute myeloid leukemia

Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia (AML) in first relapse. The study,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »